Biotech Co.* | Pharma Co. | Type/Product | Disclosed | Terms/Details |
(Symbol) | (Country) | Area | Funding | (Date) |
($M) | ||||
Applied | Elan Corp. | Alliance to commercialize AGI Dermatics' drug, Dimericine | $4 | The companies will jointly develop the drug and will license the marketing rights; Elan will make a $4M equity investments in AGI Dermatics and additional equity investments upon achievement of milestones (5/16) |
Astex | AstraZeneca | Structural biology research agreement | ND | Agreement will focus on solving novel cytochrome P450 crystal structures to be used to optimize AstraZeneca compounds (5/3) |
AVI BioPharma | Medtronic | Licensing agreement for antisense compound rights for vascular disease | ND | Deal gives Medtronic a worldwide license to a family of antisense compounds that includes Resten-NG (5/23) |
Biomira Inc. | Merck KGaA | Global collaboration agreement for 15 years for two vaccines, Theratope and BLP25 | $150 | Companies will jointly market them in the U.S.; Merck will have development and marketing rights in the rest of the world, except Israel and the Palestinian Autonomy Area (5/3) |
BioVex Ltd. | Aventis | Evaluation agreements of NeuroVEX vectors and ImmunoVEX vectors | ND | Aventis will evaluate the NeuroVEX vectors for their ability to transduce cells and tissues of the nervous system; Aventis also will evaluate ImmunoVEX vectors as a delivery vehicle for dendritic cells (6/11) |
Celera | Yamanouchi Pharmaceutical Co. Ltd. (Japan) | Five-year subscription agreement for Celera database products | ND | Yamanouchi gained access to the Celera Discovery System and the use of Celera's database products, bioinformatics systems and other discovery tools (6/25) |
Cell Pathways | Bristol-Myers Squibb Co. | Agreement to support a Phase I/II trial studying the combination of Aptosyn and Taxol plus Paraplatin as a first-line treatment for advanced non-small-cell lung cancer | ND | Companies will share the costs and data (5/3) |
Cerep SA | Aventis Pharma | Three-year drug discovery agreement | ND | Cerep will make its drug discovery platform available to Aventis for preclinical studies of new compounds (6/20**) |
ChemBridge | Sumitomo Pharmaceuticals Co. Ltd. (Japan) | Agreement providing Sumitomo access to a ChemBridge library | ND | Sumitomo gains nonexclusive access to the Pharmacophore lead discovery library (6/11) |
Chiron Corp. | Bayer Corp. | Agreement for development, manufacturing and sales agency rights to immunodiagnostic products | ND | Bayer gains the rights to the products for the detection of hepatitis C and HIV antibodies (6/14) |
Cytokinetics | GlaxoSmith- | Five-year strategic collaboration to develop novel small-molecule therapeutics targeting mitotic kinesins for applications to treat cancer and other diseases | $50 | GlaxoSmithKline will pay out $50M over a five-year research term, including a $14M up-front cash payment and a $14M purchase of Cytokinetics preferred stock; Cytokinetics also could receive milestone payments ranging from $30M to $50M per target; GSK will be responsible for worldwide development and commercialization, while Cytokinetics will receive royalties (6/25) |
DoubleTwist | Boehringer | Licensing agreement for DoubleTwist's Clustering and Alignment Tools (CAT) | ND | CAT allows users to cluster and align large volumes of expressed sequence tags and mRNA sequences into full-length gene sequences suitable for indexing and other applications (6/20) |
Entelos Inc.* | Organon (the | Research and development collaboration in rheumatoid arthritis | ND | Collaboration will use Entelos' expertise in developing large-scale mathematics models of chronic diseases that have interacting physiologic systems (5/21) |
EntreMed Inc. | Aventis | Collaboration on Phase II studies in patients with hormone-refractory prostate cancer | ND | Collaboration will study safety, dose finding and tolerability of daily oral Panzem in combination with weekly Taxotere in prostate cancer patients, and measure PSA levels and tumor responses following the combination treatment (6/25) |
Galapagos | Bayer Yakuhin | Research collaboration | ND | The proteins are encoded by newly discovered genes associated with asthma (6/12) |
Genetronics | Boehringer | Material transfer and evaluation agreement | ND | Agreement will allow BI to investigate the use of Genetronics' electroporation technology for use in cardiovascular gene therapy (6/21) |
Genmab A/S | F. Hoffmann- | Collaboration for the creation and development of human antibody therapeutics | ND | Roche gains access to Genmab's capabilities and Genmab will receive milestone and royalty payments on successful products; it also could receive rights to develop products based on disease targets (5/7) |
Genzyme | Elan Corp. | Agreement to develop one of Elan's monoclonal antibodies | ND | GTC will produce the antibody in specially bred goats that will express the therapeutic protein in their milk (5/21) |
Graffinity | Aventis Pharma | Discovery alliance to identify lead structures | ND | Financial terms were not disclosed (5/31) |
Inex | Elan | Joint venture to develop and commercialize Inex's lead anticancer product, Onco TCS | C$60 | The deal includes a C$7.5M up-front purchase of Inex stock and a profit-sharing arrangement upon the product's commercialization (4/30) |
Isis | Merck & Co. Inc. | Licensing agreement for Isis' preclinical Type II diabetes antisense drug candidate, ISIS 113715 | $50 | Isis expects to receive about $10M in revenues in 2001; the deal also includes up-front and preclinical reimbursement fees (5/23) |
KS Biomedix | MedPharm | Development agreement for a solid-dosage form of a therapeutic antibody to treat ulcerative colitis | ND | MedPharm will work on a solid-dosage form for the most advanced of two candidates (5/29) |
Ligand | TAP | Three-year research and development agreement for selective androgen receptor modulators for indications such as hypogonadism, sexual dysfunction, osteoporosis, frailty and male hormone replacement therapy | $44 | The deal is worth up to $44M for Ligand in research funding and milestones if two products are successfully developed (6/26) |
Meristem | Solvay | Exclusive licensing agreement for the use of Meristem's recombinant gastric lipase to treat digestive troubles linked with cystic fibrosis | ND | Solvay will carry out and fund Phase IIb and Phase III trials and will market the drug worldwide; Meristem will receive an up-front payment, as well as milestone payments and royalties (6/20**) |
Micromet AG | Byk Gulden | Agreement to find drug targets associated with lung cancer | ND | Micromet will use its technologies, select pathogenic cells from patients' tissue samples, then check the cells' gene expression profiles and genomic aberrations (5/8) |
NaPro | JCR | Exclusive development, supply and distribution agreement for NaPro's paclitaxel in Japan | ND | NaPro will manufacture and supply the finished drug product, and both companies will share responsibility for the JCR-funded clinical and regulatory program seeking marketing approval in Japan (6/21) |
NetGenics | Schering AG | Partnership aimed at building a comprehensive corporate gene database | ND | The database will provide a central point of access to curated and annotated gene, sequence and expression data (6/11) |
ProdiGene | Eli Lilly | Research agreement to evaluate the feasibility of using ProdiGene's maize transgenic production system | ND | The system will be used to develop and produce an enzyme that could be used as an intermediate in manufacturing processes (5/23) |
Qiagen | Shimadzu | License and purchase agreement for the Masscode system | ND | Qiagen will sell its Masscode system and license the related technology to Shimadzu for high-throughput single nucleotide polymorphism genotyping (6/14) |
SafeScience | Elan Corp. | Intent to enter a venture to further develop GBC-590 in oncology | ND | Both companies will license technology to the joint venture and Elan will make an equity investment in SafeScience (6/15) |
Scios Inc. | Medtronic | Research collaboration to study the effects of Scios' Natrecor in combination with Medtronic's heart failure devices and implantable fusion systems | ND | The first study was to begin soon in Sweden (5/9) |
Symyx | Merck & | Agreement to develop a Discovery Tools system for the discovery, identification and characterization of novel crystalline salt and polymorphic forms of drug candidates for use in clinical trials | ND | Merck will provide funding and will purchase a Polymorph Discovery Tools system upon completion and validation (6/26) |
Theratechnologies | Alza Corp. | Agreement to develop a product incorporating Alza's Macroflux skin interface technology and Theratechnologies' ThGRF (TH9507) | ND | No further details were disclosed (5/3) |
NOTES | ||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed, reported and/or available | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | ||||